About

Tianze Jiao, Ph.D., is an Assistant Professor in the Department of Pharmaceutical Outcomes & Policy at the University of Florida College of Pharmacy. He received his Ph.D. from the University of Utah and completed a postdoctoral fellowship at McGill University before joining UF in 2022. Dr. Jiao is a pharmacoepidemiologist with a focus on cardiovascular and cardiometabolic diseases. His research aims to generate real-world evidence to facilitate precision medicine by utilizing large databases such as electronic health records and claims data, along with advanced analytics including causal inference modeling, adaptive treatment strategies, and machine learning. His work involves identifying and addressing time-related bias in real-world data, assessing the comparative effectiveness and safety of interventions, and exploring drug-drug interactions. His research programs and collaborations have been funded by notable organizations such as the Canadian Institutes of Health Research, CDC, and the Bill & Melinda Gates Foundation.

Research topics

• Internal medicine
• Medicine
• Intensive care medicine
• Pharmacology

Selected publications

• Prescription Patterns for the Use of Antihypertensive Drugs for Primary Prevention Among Patients With Hypertension in the United Kingdom

  American Journal of Hypertension · 2021 · 22 citations

  1st authorCorresponding
  • Medicine
  • Internal medicine
  • Pharmacology

  BACKGROUND: Several antihypertensive drugs are available for the primary prevention of cardiovascular disease (CVD). However, existing evidence on prescription patterns was primarily generated among patients at high CVD risk with short-term follow-up, and failed to capture impacts of time and patient characteristics. Our objective was therefore to describe longitudinal prescription patterns for antihypertensive drugs for the primary prevention of CVD among patients with arterial hypertension in the United Kingdom. METHODS: This population-based cohort study used data from the Clinical Practice Research Datalink, included 660,545 patients with hypertension who initiated an antihypertensive drug between 1998 and 2018. Antihypertensive treatments were measured by drug class and described overall and in subgroups, focusing on first-line therapy (first antihypertensive drug(s) recorded after a diagnosis of hypertension) and second-line therapy (antihypertensive drug(s) prescribed as part of a treatment change following first-line therapy). RESULTS: Angiotensin-converting enzyme (ACE) inhibitors (29.0%), thiazide diuretics (22.1%), and calcium-channel blockers (CCBs) (21.0%) were the most prescribed first-line therapies. ACE inhibitors have been increasingly prescribed as first-line therapy since 2001. Men were more likely to be prescribed ACE inhibitors than women (43.5% vs. 32.1%; difference: 11.4%; 95% confidence interval [CI], 11.0%-11.8%), and Black patients were more likely to be prescribed CCBs than White patients (63.6% vs. 37.0%; difference: 26.6%; 95% CI, 24.8%-28.4%). CONCLUSIONS: Antihypertensive prescription patterns for the primary prevention of CVD among patients with hypertension are consistent with treatment guidelines that were in place during the study period, providing reassurance regarding the use of evidence-based prescribing.

  DOI

• Predictors of Asthma Control and Exacerbations: A Real-World Study

  The Journal of Allergy and Clinical Immunology In Practice · 2021 · 19 citations

  • Medicine
  • Intensive care medicine
  • Internal medicine
  DOI

Frequent coauthors

• Hui Shao

  64 shared

• Jingchuan Guo

  Center for Drug Evaluation and Research

  30 shared

• Joshua D. Brown

  Center for Drug Evaluation and Research

  24 shared

• Piaopiao Li

  Center for Drug Evaluation and Research

  22 shared

• Hans K. Ghayee

  Malcom Randall VA Medical Center

  15 shared

• Dawei Guan

  University of Florida

  13 shared

• Alaa Alshehri

  Center for Drug Evaluation and Research

  12 shared

• Joseph Biskupiak

  University of Utah

  11 shared

Education

• Ph.D., Pharmaceutical Outcomes & Policy

  University of Florida

  2015

• M.S., Pharmaceutical Outcomes & Policy

  University of Florida

  2011

• B.S., Pharmacy

  University of Florida

  2009

Similar researchers at University of Florida

• Steven T DeKoskyh-162
• Matthew Farrerh-133
• George Christouh-133
• Mark A Atkinsonh-129
• Christiaan Leeuwenburghh-125